Drug intelligence / Profile preview

SM3

Development stage: Preclinical
Lead developer: Imperial Cancer Research Fund
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**SM3** is a murine IgG1 monoclonal antibody that recognizes the PDTRP core-peptide epitope within the tandem-repeat region of under-glycosylated tumor-associated mucin 1. It was developed as an investigational radioimmunoscintigraphy antibody: when labeled with technetium-99m, indium-111, or iodine-123, it preferentially accumulated in MUC1-expressing adenocarcinomas and was evaluated for preoperative imaging of ovarian cancer, breast cancer, and associated lymph-node disease. SM3 itself is the unlabeled antibody; isotope-labeled SM3 preparations are radiopharmaceutical diagnostic agents. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/2283483/))

Other names: SM-3SM3SM 3stripped mucin 3

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on SM3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM3.

Explore the full profile